Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALZ-101
Therapeutic Area: Neurology Product Name: ALZ-101
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
The study design is today presented on a poster titled: First in Human study with ALZ-101, a unique and highly specific therapeutic vaccine against the neurotoxic oligomeric form of Aβ 1-42.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cobra Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
ACD856 significantly increases the levels of key neurotransmitters in the hippocampus - an area known to play a critical role in memory processing .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020
Details:
The study demonstrated that the clinical candidate, ACD856, in NeuroRestore platform can effectively prevent the memory impairment associated with normal aging in animals.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
